48 results about "Thyroid gland cancer" patented technology

The invention relates to the preparation of 131I-thyroid stimulating hormone (TSH) and an application thereof, belonging to the field of radionuclide therapeutic drugs. The compound 131I-thyroid stimulating hormone is a radioiodine marker for thyroid stimulating hormone with pathoclisis in vivo acting on thyrocyte. A preparation method of the 131I-thyroid stimulating hormone comprises the following steps of: carrying out iodine 131 marking on the thyroid stimulating hormone by utilizing a chloramine-T method, a peroxide oxidation method or an iodogen method, and introducing radionuclide iodine 131 for treatment into tyrosine residues in thyroid stimulating hormone molecules. The marking rate of the prepared 131I-TSH is 85.9 percent, the radiochemical purity after purification achieves more than 90 percent, and the prepared 131I-TSH can be stored stably for more than one week at room temperature; the 131I-TSH is mainly metabolized through the liver and excreted through the kidneys; the percentage of ID/g of the 131I-TSH in the thyroid gland is not obviously reduced in four hours; and the 131I-TSH can be concentrated in thyroid gland issues sealed by an iodine solution. Concerning low/undifferentiated thyroid tumours incapable of iodine uptake, the 131I-TSH can increase the radioiodine uptake of thyroid gland cancer cells, and the radioiodine 131 can be chosen for treatment.

The invention relates to a biomarker for preoperative identification of benign and malignant thyroid nodules, a kit and application thereof. The level of 17 metabolites in peripheral blood plasma of a thyroid nodule patient is detected through metabonomics analysis, and omics analysis and a machine learning method are combined to construct a diagnosis model and evaluate the thyroid cancer diagnosis efficiency by using a subject working curve (ROC). The area of the metabolic marker combination diagnosis model composed of the metabolites under the ROC curve in thyroid nodule diagnosis can reach 95.05%, the sensitivity and specificity are both higher than 88%, and the metabolite marker combination diagnosis model can be applied to identification of thyroid benign and malignant nodules.

The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

The invention discloses a thyroid cancer pathological image classification method based on deep learning, and mainly solves the problem of poor thyroid cancer pathological image classification effectof an existing method. According to the implementation scheme, the method comprises the following steps: reading a thyroid pathology image database, extracting low-level convolution and pooling features by a receptive field network, and fusing the features to obtain fused low-level features; extracting high-level features, namely predicted category vectors, from the fused low-level features through a capsule network; updating the category vector through a dynamic routing algorithm to obtain a final category vector, and calculating the modulus of the category vector through a compression activation function; carrying out image reconstruction on the vector with the maximum modulus value through a decoding reconstruction network; iteratively updating weights in the receptive field network andthe capsule network to complete model training; and finally, inputting a thyroid pathological image to be classified into the trained model to obtain a final classification result. The invention improves the classification accuracy of the thyroid cancer pathological images and can be used for computer-aided diagnosis.

The invention relates to a methylation marker for identification of benign and malignant thyroid tumors and evaluation of follicular tumors with uncertain malignant potential, and a method for constructing an identification model for benign and malignant thyroid tumors. The method comprises the following steps of: (1) acquiring the methylation levels of candidate sites or fragments in genome DNAsof a tumor sample and a control sample; (2) processing the methylation levels of the sites or fragments by using at least one algorithm selected from a group consisting of mhl, mhl3, umhl and pdr; (3)screening out a site or fragment having significant difference between the processed methylation level of the tumor sample and the processed methylation level of the control sample, and screening outan optional corresponding algorithm, wherein the site or fragment is the methylation marker; and (4) constructing the model for identifying benign and malignant thyroid cancer according to the processed methylation levels of the methylation marker.

The invention discloses a 22-nor-stigmasta thiosemicarbazone compound and a preparing method and application thereof. The structural formula of the 22-nor-stigmasta thiosemicarbazone compound is shown in the description. In vitro cancer cell growth and proliferation activity inhibition tests show that the prepared 22-nor-stigmasta thiosemicarbazone compound has a remarkable inhibition effect on various tumor cell strains such as human nipple thyroid gland cancer cells, human oral cavity epidermoid carcinoma cells and cervical cancer. Meanwhile, the 22-nor-stigmasta thiosemicarbazone compound is free of cytotoxicity on human kidney epithelial cells (HEK293T) and can be used for preparing medicine for treating cancer.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

The invention discloses a product and a method for identifying, diagnosing and evaluating thyroid cancer. In the specific embodiment of the invention, IgG in body fluid is separated, then N-carbohydrate chains on IgG are dissociated through glycosidase, and the expression quantity difference of the N-carbohydrate chains on IgG in thyroid cancer and non-cancer control (healthy and benign nodule) body fluid is compared by utilizing a mass spectrum-based analysis method. The inventor finds that compared with non-cancer control, the expression quantities of three N sugar chains (H3N5F1, H4N5F1 and H5N5F1) in plasma of a thyroid cancer patient are respectively and obviously increased, meanwhile the other N sugar chain H4N4F1 is obviously reduced. That is to say, differently expressed IgG N-carbohydrate chain can effectively distinguish thyroid cancer and non-cancer control, and the combination of H3N5F1, H4N5F1 and H5N5F1 also has the potential of early diagnosis of thyroid cancer. The method is high in sensitivity, a required blood sample is easy to obtain, the accuracy is high when the method is used for thyroid cancer differential diagnosis, and the method has important application value.

Disclosed herein are novel chimeric antigen receptors (CARs) targeting human LHR, B7-H4, HLA-G, or HLA-DR, and therapeutic methods of their use. LHR, B7-H4, HLA-G, or HLA-DR are expressed in the context of many human cancers including thyroid, prostate, colon, breast, ovarian, and renal cancers, as well as B-cell leukymias and lymphomas.

It is found for the first time that down-regulation is conducted in thyroid cancer tissues, down-regulation is more obvious in thyroid cancer tissues with lymph node metastasis, MAPK8IP1P2 down-regulation indicates poor prognosis of thyroid cancer patients, and overexpression of MAPK8IP1P2 can inhibit in-vivo tumorigenesis of thyroid cancer cells. Based on the new discovery, the MAPK8IP1P2 can beused for diagnosing whether a subject suffers from thyroid cancer or not, lymph node metastasis of thyroid cancer and survival prognosis, thyroid cancer tumorigenesis is inhibited through the medicinefor overexpression of the MAPK8IP1P2, and a new strategy is provided for diagnosis, prognosis and treatment of the thyroid cancer.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human SHCBP1 gene used as a target in preparing a thyroid cancer treatment medicine orpreparing a thyroid cancer diagnosis medicine. Through the broad and deep research, the invention discovers that after the expression of the human SHCBP1 gene is down-regulated by adopting an RNAi method, the multiplication of thyroid cancer cells can be effectively inhibited, the cell apoptosis is promoted, and the growth process of thyroid cancer can be effectively controlled. The siRNA or a nucleic acid building body and a slow virus containing the siRNA can specifically inhibit a multiplication capacity of the thyroid cancer cells, inhibit a tumor formation capacity of the thyroid cancer cells in a human body, promote the thyroid cancer cell apoptosis, inhibit the cloning of the thyroid cancer cells, inhibit a thyroid cancer cell metastasis capacity, inhibit a thyroid cancer cell transfer capacity and change the period distribution of the thyroid cancer cells so as to treat the thyroid cancer, so that a new direction is opened for thyroid cancer treatment.

The invention relates to the technical field of medical diagnostics, in particular to a blood micromolecular metabolite atlas for identifying papillary thyroid cancer, benign goiter or normal person, and a producing method thereof. The micromolecular metabolite comprises two blood metabolism markers, namely sphinganine 1-phosphate and hydroxybutyric acid which respectively have molecular weight of 453.2855 and 569.3481 as well as corresponding ions detected by mass spectroscopy of 454.2928 and 570.3547. Clinical experiment proves that the atlas has thyroid cancer judgment accuracy rate of 82% and non-cancer (benign goiter and normal person) judgment accuracy rate of 75.3%. The method provided by the invention has the advantages of high sensitivity and high flux, overcomes the defect that a non-invasive diagnosis method for diagnosing benign and malignant thyroid tubercle is lacking clinically at present, and is suitable for screening and assistant diagnosis of thyroid cancer.

The invention discloses an application of 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indole-3-yl) ethanone or pharmaceutically acceptable salt thereof in preparation ofa medicine for treating or preventing tumor diseases. The product is used for relieving and/or adjunctively treating and/or treating myeloma, leukemia, lymphoma, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, lung cancer, liver cancer, skin cancer, rectal cancer, prostate cancer, thyroid cancer and other tumors. The 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3-yl) ethanone has a remarkable specific inhibition effect on PI3K gamma (polyisocyanurate).

The invention discloses an endoscopic thyroid hanging tool. According to the endoscopic thyroid hanging tool, the problem that no sufficient space for a surgery is provided during lymph node dissection of a thyroid cancer lateral neck region in the prior art is mainly solved. The endoscopic thyroid hanging tool comprises a hanger and a suction pipe, wherein the hanger is of a non-sealed frameworkstructure, is used for separating flaps in a lateral neck region in a hanging manner so as to establish a cavity and comprises a first transverse plate, a vertical plate and a second transverse plate,the first transverse plate is transversely arranged, the vertical plate is connected with the first transverse plate and is vertically arranged at one end of the first transverse plate, and the second transverse plate is connected with the vertical plate and is inserted into the lateral neck region; and the suction pipe is arranged on the second transverse plate. The endoscopic thyroid hanging tool has the technical effects that traction injury of skin at a notch is little, postoperative hyperplasia of a notch scar is reduced, the structure is simple, and mounting is convenient.

The present invention relates to a combination of at least two components, component A and component B, component A being an AhR inhibitor and component B being pemmumab or Nasumab. Another aspect of the invention relates to a combination of three components, component A, component B and component C; the component A is an AhR inhibitor, the component B is pemmumab or Nasumab, and the component C is another agent. The invention further relates to the use of such a combination as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, the compounds are useful in the treatment or prevention of breast cancer, respiratory tract cancer, brain cancer, reproductive organ cancer, digestive tract cancer, urinary tract cancer, eye cancer, liver cancer, skin cancer, kidney cancer, head and neck cancer, thyroid cancer, parathyroid cancer, and their distal metastases, lymphoma, sarcoma and leukemia.

The invention provides application of Perospirone or a derivative thereof and a pharmaceutical composition containing the Perospirone or the derivative thereof in preparation of drugs for preventing and/or treating tumors. The Perospirone has an obvious growth inhibition effect on various human tumor cells, and has an obvious inhibition effect on tumor growth of nude mice inoculated with human tumor cells. The compound has broad-spectrum antitumor activity, and experiments show that the compound has good inhibitory activity on breast cancer, ovarian cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, leukemia, lymphoma, esophageal cancer, thyroid cancer, nasopharynx cancer, kidney cancer, glioma, cervical cancer, prostatic cancer and other tumors; and it is shown that the Perospirone and the derivative thereof can become antitumor drugs.